NANOBIOTIX SIGNS A 40 M€ NON-DILUTIVE
FINANCING AGREEMENT WITH THE EUROPEAN INVESTMENT
BANK
- Acceleration of company's priorities in head & neck
clinical development and market preparation
- Non-dilutive funding to expand the Company cash
visibility beyond 2019
Paris, France and Cambridge, Massachusetts,
July 26, 2018 - NANOBIOTIX (Euronext: NANO - ISIN:
FR0011341205), a late clinical-stage nanomedicine company
pioneering new approaches in the treatment of cancer, announced
today that the Company launched a non-dilutive financial
partnership with the European Investment Bank (EIB) to boost its
research, development and innovation activities.
The financing agreement will allow the Company
to borrow up to 40 M€ through loan over the coming five years
subject to achieving a set of agreed performance criteria.
The transaction with Nanobiotix was made
possible by the support of the European Fund for Strategic
Investments (EFSI). EFSI is the central pillar of the Investment
Plan for Europe, under which the EIB Group and the European
Commission aim to act as strategic partners to boost the
competitiveness of the European economy.
This financing agreement will enable Nanobiotix
to accelerate both the development of NBTXR3 clinical trial in the
head and neck cancers indication and to support the European
go-to-market strategy.
The financing structure has been tailored to
Nanobiotix specific needs thanks to the EU guarantee under the
Juncker Plan, which key objectives include supporting innovative
companies and helping their development in Europe but also to the
EIB's financial expertise in this type of operation.
Commissioner Vytenis Andriukaitis said:
"Cancer is the second-highest cause of death in the EU and with
Europe's ageing population, fighting cancer will undoubtedly remain
a priority in the years to come. We need to have innovative
and dedicated research to always be in search of new treatments.
Nanoparticle based cancer treatment research funding is one example
of how serious we are in fighting cancer, with the significant
support from the EIB to finance research and innovation."
"This project is a great fit with the Juncker
Plan and is very important for European innovation." emphasised EIB
Vice-President Ambroise Fayolle. "Innovation, and support
for innovative companies, is what the EU guarantee under the
Investment Plan for Europe is about, and financing research into
cancer treatment is one of the most rewarding things a Bank can do.
The EIB's mission is to improve people's lives, I think this is an
excellent example of that."
Philippe Mauberna, CFO Nanobiotix, added:
"We are pleased to have the European Investment Bank on board as a
new financing partner. This loan will significantly enhance our
financial visibility without diluting our shareholders in the
medium term. This new partnership is another value recognition of
the product the Company wants to bring to market to help millions
of cancer patients." *** About
NBTXR3NBTXR3 is a first-in-class product designed to destroy,
when activated by radiotherapy:
- tumors through physical cell death
- metastasis due to immunogenic cell death leading to activation
of the immune system.
NBTXR3 has a high degree of biocompatibility,
requires one single administration before the whole radiotherapy
treatment and has the ability to fit into current worldwide
standards of radiation care.
The broad clinical program includes 10 patient
population evaluated in 7 clinical trials.In June 2018, the company
has established the human proof of concept on this First in class
product in Soft tissue Sarcoma Phase III clinical trial.
NBTXR3 is actively being evaluated in head and
neck cancer with locally advanced squamous cell carcinoma of the
oral cavity or oropharynx in elderly and frail patients unable to
receive chemotherapy or cetuximab with very limited therapeutic
options. The Phase I/II trial has already delivered very promising
results regarding the local control of the tumors.
Nanobiotix is running an Immuno-Oncology
development program . In the U.S., the Company received the FDA's
approval to launch a clinical study of NBTXR3 activated by
radiotherapy in combination with anti-PD1 antibodies in lung, and
head and neck cancer patients (head and neck squamous cell
carcinoma and non-small cell lung cancer).
The other ongoing studies are treating patients
with liver cancers (hepatocellular carcinoma and liver metastasis),
locally advanced or unresectable rectal cancer in combination with
chemotherapy, head and neck cancer in combination with concurrent
chemotherapy, and prostate adenocarcinoma.
The first market authorization process (CE
Marking) is ongoing in Europe in the soft tissue sarcoma
indication.
About NANOBIOTIX -
www.nanobiotix.com Incorporated in 2003, Nanobiotix is a leading,
late clinical-stage nanomedicine company pioneering new approaches
to significantly change patient outcomes by bringing nanophysics to
the heart of the cell.
The Nanobiotix philosophy is one rooted in
designing pioneer physical based approaches to bring highly
effective and generalized solutions to address high unmet medical
needs and challenges.
The Company's first-in-class, proprietary lead
technology, NanoXray, aims to expand radiotherapy benefits for
millions of cancer patients. Furthermore, the Company's
Immuno-Oncology program has the potential to bring a new dimension
to cancer immunotherapies.
Nanobiotix is listed on the regulated market of
Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg:
NANO: FP). The Company's Headquarters are based in Paris, France,
with a U.S. affiliate in Cambridge, MA, and European affiliates in
Spain and Germany.
About the European Investment Bank
(EIB) - http://www.eib.org Created by the Treaty of Rome in
1958, the EIB is the European Union's bank, which, together with
its dedicated SME support subsidiary the European Investment Fund
(EIF), forms the EIB Group.
The EIB Group is a key player in reviving
Europe's - and particularly France's - economy through investment.
Thanks to its reliable expertise and the financial attractiveness
of its AAA rating, the EIB Group has doubled the volume of its
activities in France since 2012 (reaching EUR 8.6bn in 2017), not
only supporting businesses and innovation but also financing
investment in strategic sectors such as climate action, energy,
healthcare, housing, education for young people and training
infrastructure. Since 2015, the EIB Group has been the operator of
the Investment Plan for Europe, commonly known as the Juncker
Plan.
The Investment Plan for Europe, or Juncker Plan,
is one of Jean-Claude Juncker's Commission's top priorities. It
focuses on boosting investments in Europe to create jobs and growth
by making smarter use of new and existing financial resources,
removing obstacles to investment and providing greater visibility
and technical assistance to investment projects. The European Fund
for Strategic Investments (EFSI), which is the central pillar of
the Investment Plan for Europe, enables the EIB Group to invest
in more, often riskier, projects with high added value.
Contact
Nanobiotix |
Sarah GaubertDirector, Communication & Public
Affairs+33 (0)1 40 26 07 55sarah.gaubert@nanobiotix.com
/contact@nanobiotix.com |
Noël Kurdi Director, Investor
Relations +1 (646) 241-4400 noel.kurdi@nanobiotix.com /
investors@nanobiotix.com |
Ricky Bhajun Investor Relations Europe +33 (0)1 79 97 29 99
ricky.bhajun@nanobiotix.com / investors@nanobiotix.com |
Media relations Nanobiotix |
|
France - Springbok ConsultantsMarina Rosoff+33
(0)6 71 58 00 34marina@springbok.fr |
|
United States - RooneyPartners Marion Janic +1
(212) 223-4017mjanic@rooneyco.com |
|
|
EIB Press contact |
|
Tim Smit
t.smit@eib.org tel.: +352 4379 89076; mobile: +352 691 28 64
23 |
|
Website:
www.eib.org/pressPress Office:+352 4379 21000press@eib.org
|
|
DisclaimerThis press release contains certain
forward-looking statements concerning Nanobiotix and its business.
Such forward-looking statements are based on assumptions that
Nanobiotix considers to be reasonable. However, there can be no
assurance that the estimates contained in such forward-looking
statements will be verified, which estimates are subject to
numerous risks including the risks set forth in the reference
document of Nanobiotix filed with the French Financial Markets
Authority (Autorité des Marchés Financiers) under number D.17-0470
on April 28, 2017 as well as in its 2017 annual financial report
filed with the French Financial Markets Authority on March 29, 2018
(a copy of which is available on www.nanobiotix.com) and to the
development of economic conditions, financial markets and the
markets in which Nanobiotix operates. The forward-looking
statements contained in this press release are also subject to
risks not yet known to Nanobiotix or not currently considered
material by Nanobiotix. The occurrence of all or part of such risks
could cause actual results, financial conditions, performance or
achievements of Nanobiotix to be materially different from such
forward-looking statements.
This press release and the information that it
contains do not constitute an offer to sell or subscribe for, or a
solicitation of an offer to purchase or subscribe for, Nanobiotix
shares in any country. At the moment NBTXR3 does not bear a CE mark
and is not permitted to be placed on the market or put into service
until NBTXR3 has obtained a CE mark.
Nanobiotix (EU:NANO)
Historical Stock Chart
From Apr 2024 to May 2024
Nanobiotix (EU:NANO)
Historical Stock Chart
From May 2023 to May 2024